A meta-analysis of long non-coding RNAs as novel serum biomarkers for the diagnosis of hepatocellular carcinoma

王秀月; 赵　川; 陈　彻

doi:10.19401/j.cnki.1007-3639.2018.03.010

您当前的位置：

首页 >

文章列表页 >

A meta-analysis of long non-coding RNAs as novel serum biomarkers for the diagnosis of hepatocellular carcinoma

更新时间：2026-01-27

- A meta-analysis of long non-coding RNAs as novel serum biomarkers for the diagnosis of hepatocellular carcinoma
- China Oncology Vol. 28, Issue 3, Pages: 229-235(2018)
- 作者机构：
  
  甘肃中医药大学临床医学院,甘肃,兰州,730000
- 作者简介：
- 基金信息：
- DOI：10.19401/j.cnki.1007-3639.2018.03.010
  CLC： R735.7
- Published Online：11 April 2018，
  
  Published：11 April 2018
- 稿件说明：
移动端阅览
王秀月,赵　川,陈　彻,等. 长链非编码RNA作为肝细胞癌诊断新型血清标志物的meta分析[J]. 中国癌症杂志, 2018, 28(3): 229-235.

王秀月, 赵　川, 陈　彻. A meta-analysis of long non-coding RNAs as novel serum biomarkers for the diagnosis of hepatocellular carcinoma[J]. China Oncology, 2018, 28(3): 229-235.
王秀月,赵　川,陈　彻,等. 长链非编码RNA作为肝细胞癌诊断新型血清标志物的meta分析[J]. 中国癌症杂志, 2018, 28(3): 229-235. DOI： 10.19401/j.cnki.1007-3639.2018.03.010.

王秀月, 赵　川, 陈　彻. A meta-analysis of long non-coding RNAs as novel serum biomarkers for the diagnosis of hepatocellular carcinoma[J]. China Oncology, 2018, 28(3): 229-235. DOI： 10.19401/j.cnki.1007-3639.2018.03.010.

摘要

背景与目的：长链非编码RNA（long non-coding RNA，lncRNA）是一类具有巨大前景的新型肿瘤标志物。该研究旨在疏理lncRNA用于诊断肝细胞癌（hepatocellular carcinoma，HCC）的研究概况。方法：使用计算机检索PubMed、EMbase、Cochrane Library、CBM、CNKI及万方数据库，检索时限均从建库至2017年2月。纳入的研究通过诊断准确性研究质量评价工具（Quality Assessment of Diagnostic Accuracy Studies2，QUADAS-2）进行质量评价。采用随机效应模型合并分析灵敏度、特异度、阳性似然率和阴性似然率。通过受试者工作特征（receiver operating characteristic，ROC）曲线和曲线下面积（area under curve，AUC）估计整体检验效能。数据采用Stata 12.0和Meta-Disc 1.4软件进行统计分析。结果：最终共纳入13个研究，其中，HCC患者1 296例，健康对照者1 304人。整体lncRNA诊断HCC的灵敏度、特异度、阳性似然率和阴性似然率分别为83%（95%CI：81%~85%）、82%（95%CI：80%~84%）、5.32（95%CI：3.37~8.42）和0.21（95%CI：0.15~50.28），对应的AUC为0.91。结论：LncRNA对于HCC具有高度的诊断价值，并且其表达可作为确诊HCC的辅助生物标志物。

Abstract

Background and purpose: Long non-coding RNAs (lncRNA) are outstanding as novel cancer biomarkers with great prospects. Hence

we aimed to summarize the overall diagnostic assessment of lncRNAs for hepatocellular carcinoma (HCC). Methods: A systematic search was performed in PubMed

EMbase

Cochrane Library

CBM

CNKI and Wanfang database from establishment of the database to February 2017. The quality of included studies was evaluated using the Quality Assessment of Diagnostic Accuracy Studies 2 (QUADAS-2) checklist. The pooled sensitivity

specificity

positive likelihood ratio (LR) and negative LR were analyzed using random effect model. The overall test efficacy was estimated using the summary receiver operating characteristic (ROC) curve and the area under the curve (AUC). Statistical analysis was conducted using Stata 12.0 and Meta-Disc 1.4 software. Results: A total of 13 studies involving 1296 patients with hepatocellular carcinoma and 1304 healthy controls were finally included. For overall lncRNA

the pooled sensitivity

specificity

positive LR and negative LR to predict HCC patients were 83% (95%CI: 81%-85%)

82% (95%CI: 80%-84%)

5.32 (95%CI: 3.37-8.42) and 0.21 (95%CI: 0.15-50.28)

respectively

corresponding to an AUC of 0.91. Conclusion: LncRNA have high diagnostic value for HCC

and their expressions can be used as auxiliary biomarkers in confirming HCC.

关键词

Keywords

references

Views

1858

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Mechanism of LINC00601 in regulating sensitivity of hepatocellular carcinoma cells to oxaliplatin chemotherapy

Guidelines for breast cancer diagnosis and treatment by China Anti-Cancer Association (2026 edition)

Risk of cancer therapy-related cardiotoxicity following the use of PD-1/PD-L1 inhibitors combined with chemoradiotherapy compared with chemoradiotherapy in solid tumors: a systematic review and Meta-analysis

Research status and progress of third-line treatment for metastatic colorectal cancer

Microwave ablation versus hepatic resection in potentially resectable colorectal liver metastasis: a systematic review and meta-analysis

Related Author

Keshu HU

Wenfeng LIU

Feng ZHANG

Bing QUAN

Xin YIN

The Society of Breast Cancer China Anti-Cancer Association

Breast Oncology Group of the Oncology Branch of the Chinese Medical Association

ZHENG Jinmei

Related Institution

Department of Liver Oncology, Zhongshan Hospital, Fudan University

Liver Cancer Institute, Zhongshan Hospital, Fudan University

Department of Oncology, Beijing Friendship Hospital Capital Medical University

Department of Pathology, School of Basic Medical Sciences of Fujian Medical University

Zhangzhou Changtai District Hospital

AI问答

⁰